ImmunoGen (IMGN) Sells 7.8M Shares To Ziff Asset Management at $3.20/Sh
More News related to IMGN
- ImmunoGen, Inc. Announces Webcast of Presentation at the Thomas Weisel Partners Healthcare Conference 2008
- ImmunoGen, Inc. Announces sanofi-aventis Licenses Expanded Access to the Company's TAP Technology
- David Moenning's Daily State of the Markets: 8/8
- ImmunoGen (IMGN) Misses Q2 View By 3c
- ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2008 Financial Results
More News related to Equity Offerings
- Canada's Government Supports Community Organizations Targeted by Hate Crime - Ontario
- Public Health Agency of Canada: Scientific Discovery Holds Promise of BSE Test for Live Animals
- The 2008 Bon Appetit Magazine Awards Celebrate Today's Best Chefs, Tastemakers and Food Artisans
- Prepare for Emergency and Disaster Communications Needs With SPOT Satellite Messenger
- Intersil's Ultra-Flexible Dual Protocol Transceivers Deliver High ESD Protection in Tiny Form Factor
ImmunoGen, Inc. (Nasdaq: IMGN) announced that Ziff Asset Management, L.P. has purchased approximately 7.8 million shares of ImmunoGen’s common stock at $3.20 per share.
Proceeds to ImmunoGen from the offering, net of estimated expenses, are expected to be approximately $24.7 million.
Shares of ImmunoGen closed at $3.01 per share on Friday.
Related Categories
Equity OfferingsStocks Mentioned
+0.13Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
